照護現場診斷市場規模、佔有率和成長分析：按產品類型、樣本、最終用戶、地區 - 產業預測，2024-2031 年

2022年，全球照護現場診斷市場規模將為476.4億美元，預測期內（2024-2031年）複合年成長率為6.1%，從2023年到2031年的505.4億美元。年為811.7 億美元。

照護現場診斷 (POCD) 市場是指在患者附近或患者照護端進行的醫療測試，提供通常在幾分鐘內完成的快速診斷，以支援分類的臨床決策。該市場包括設計和製造各種診斷設備和測試，以滿足各種醫療保健環境的需求，包括醫院、診所、門診護理中心，甚至居家醫療。 POCD 具有許多優勢，包括更快的周轉時間、減少對中心實驗室的依賴、改善病患治療效果和成本效率。影響 POCD 市場的關鍵因素包括患者群體擴大、診斷材料產量增加、檢測服務需求增加以及人口老化加劇。人們對該疾病早期發現和管理的認知不斷提高也支持了 POCD 的發展。市場成長的主要驅動力是具有生物感測器和連接功能的手持/可攜式設備的技術進步。此外，實驗室晶片技術提高了就地檢驗的準確性、速度和可用性，進一步促進了市場擴張。 COVID-19 大流行顯著加速了市場的發展，尤其是快速抗原測試和分子診斷，從而改善了病毒檢測。然而，法律障礙、報銷問題和品管問題等挑戰可能會阻礙市場進步。儘管面臨這些挑戰，由於技術的不斷進步、醫療保健分散化的趨勢以及對個人化和高效醫療診斷的需求不斷成長，全球 POCD 市場仍有望實現顯著成長。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價格分析
• 價值鏈分析
• 供應鏈分析
• 市場生態系統
• Start-Ups分析
• 專利分析
• 案例研究分析
• 客戶和購買標準分析
• 監管環境
• 創新矩陣
• 重點投資分析
• 關鍵成功因素
• 市場魅力指數
• 競爭程度

照護現場診斷市場：按樣本

• 市場概況
• 血液樣本
• 尿液樣本
• 鼻/咽拭子
• 其他樣品

照護現場診斷市場：按產品

• 市場概況
• 血糖值監測產品
  • 條
  • 儀表
  • 採血針/穿刺裝置
• COVID-19 檢測產品
• 心臟代謝監測產品
  • 心臟標記檢測產品
  • 血氣/電解質檢測產品
  • HBA1C檢測產品
• 傳染病檢查產品
  • HIV檢測產品
  • 呼吸道傳染病檢查產品
  • 丙型肝炎檢測產品
  • 醫療感染檢測產品
  • 流感檢測產品
  • 熱帶疾病檢測產品
  • 性行為感染檢測產品
  • 梅毒檢測產品
  • 梅毒檢測產品
  • 披衣菌感染衣原體檢測產品
  • 單純皰疹病毒（HSV）檢測產品
  • 結核
  • 困難梭狀芽孢桿菌傳染病檢測產品
  • 其他傳染病檢查產品
• 凝血監測產品
  • PT/INR檢測產品
  • ACT/APTT測試產品
• 懷孕和生殖檢測產品
  • 妊娠測試產品
  • 不孕不孕檢測產品
  • 腫瘤/癌症標記檢測產品
  • 尿液檢查產品
  • 膽固醇檢測產品
  • 血液檢測產品
  • 藥物濫用檢測產品
  • 甲狀腺刺激素檢測產品
  • 大便潛血試驗產品
  • 其他產品

照護現場診斷市場：依最終使用者分類

• 市場概況
• 臨床實驗室
• 門診醫療設施/醫生診所
• 藥局、零售診所和電子商務平台
• 醫院、重症監護中心、緊急護理中心
• 居家醫療/自我檢查
• 其他最終用戶

照護現場診斷市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Abbott Laboratories（US）
• Siemens Healthineers AG（Germany）
• Quidel Corporation（US）
• F. Hoffman-La Roche Ltd.（Switzerland）
• Danaher Corporation（US）
• Becton, Dickinson and Company（US）
• Chembio Diagnostics（US）
• EKF Diagnostics（UK）
• Trinity Biotech plc（Ireland）
• Instrumentation Laboratory（US）
• Nova Biomedical（US）
• PTS Diagnostics（US）
• Sekisui Diagnostics（US）
• Thermo Fisher Scientific（US）
• BioMerieux SA（France）
• Beckman Coulter, Inc.（US）
• Hologic, Inc.（US）
• Cepheid（US）
• Ortho Clinical Diagnostics（US）
• Bio-Rad Laboratories, Inc.（US）
• Trividia Health（US）
• Chembio Diagnostic Systems, Inc.（US）

Global Point of Care Diagnostics Market size was valued at USD 47.64 Billion in 2022 and is poised to grow from USD 50.54 Billion in 2023 to USD 81.17 Billion by 2031, at a CAGR of 6.1% during the forecast period (2024-2031).

The Point of Care Diagnostics (POCD) market refers to medical testing conducted close to or at the site of patient care, falling under the category of rapid diagnostics typically completed within minutes to aid in clinical decision-making. This market encompasses the design and manufacturing of a variety of diagnostic equipment and assays tailored to the needs of different healthcare settings, including hospitals, clinics, ambulatory care centers, and even homecare. Point-of-care diagnostics offer numerous advantages, such as quicker turnaround times, reduced reliance on centralized laboratories, improved patient outcomes, and cost efficiency. Key factors influencing the POCD market include an expanding patient base, increased production of diagnostic materials, rising demand for laboratory services, and a growing aging population. The heightened awareness of early disease detection and management also fuels the development of POCD. A major driver of market growth is technological advancement, featuring handheld/portable devices with biosensors and connectivity capabilities. Additionally, lab-on-a-chip technology enhances the accuracy, speed, and availability of point-of-care tests, further contributing to market expansion. The COVID-19 pandemic significantly accelerated the market, particularly through rapid antigen testing and molecular diagnostics, thereby improving viral detection. However, challenges such as legal barriers, reimbursement issues, and quality control concerns could hinder market progress. Despite these challenges, the global POCD market is poised for substantial growth, driven by continuous technological advancements, the trend toward healthcare decentralization, and the increasing demand for personalized and efficient medical diagnostics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Point of Care Diagnostics (POCD) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Point of Care Diagnostics (POCD) Market Segmental Analysis

Point of care diagnostics market is segmented based on Sample, Product, End Users, and Region. Based on Sample, the market is segmented as Blood Sample, Urine Sample, Nasal and Oropharyngeal Swabs Sample, And Other Samples. Based On Product, The Market Is Further Segmented Into Glucose Monitoring Products (Strips, Meters, Lancets & Lancing Devices), Covid-19 Testing Products, Cardiometabolic Monitoring Products (Cardiac Marker Testing Products, Blood Gas/Electrolyte Testing Products, Hba1c Testing Products), Infectious Disease Testing Products (HIV Testing Products, Respiratory Infection Testing Products, Hepatitis C Testing Products, Healthcare-associated Infection Testing Products, Influenza Testing Products, Tropical Disease Testing Products, Sexually Transmitted Disease Testing Products, Syphilis Testing Products, Syphilis Testing Products, Chlamydia Trachomatis Testing Products, Herpes Simplex Virus (HSV) tEsting Products, Tuberculosis, Clostridium Difficile Infection Testing Products, Other Infectious Disease Testing Products), Coagulation Monitoring Products (PT/INR Testing Products, ACT/APTT Testing Products), Pregnancy & Fertility Testing Products (Pregnancy Testing Products, Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Product, Drugs-of-abuse Testing Products, Thyroid-stimulating Hormone Testing Products, Fecal Occult Testing Products, Other Products. Based On End Users, Point Of Care Diagnostics Market Is Further Segmented into Clinical Laboratories, Ambulatory Care Facilities and Physicians Offices, Pharmacies, Retail Clinics, And E-commerce Platforms, Hospitals, Critical Care Centers, And Urgent Care Centers, Home Care Settings And Self-testing, Other End Users. Based on region, the market is segmented into North America, Asia-Pacific, Europe, Latin America, Middle East and Africa.

Drivers of the Global Point of Care Diagnostics (POCD) Market

Globally, there has been a significant rise in the prevalence of chronic diseases such as cardiovascular issues, diabetes, and various infectious diseases. One of the key factors driving the demand for point-of-care diagnostics during the forecast period is the increasing occurrence of these disorders. According to the United Nations, approximately 38 million people were living with HIV/AIDS in 2019, including 1.8 million children and 36.2 million adults. Additionally, human respiratory syncytial virus (RSV) is a common cause of respiratory tract infections. The global adult diabetic population is projected to reach 643 million by 2030 and 783 million by 2045. The substantial increase in the prevalence of diabetes and other chronic diseases worldwide has created a demand for rapid point-of-care diagnostics aimed at effectively managing these conditions. Consequently, the market is expected to experience positive growth globally.

Restraints in the Global Point of Care Diagnostics (POCD) Market

Due to a high number of pre- and post-analytical errors, point-of-care test results often do not align accurately with central lab procedures. Pre-analytical errors can arise from unsuitable indications for performing the test, inappropriate sampling times and techniques, inadequate information about patient conditions, and other factors such as fasting before functional tests or differences in posture during similar tests. Post-analytical errors include insufficient technical validation, incorrect result assignment, and data storage issues. Point-of-care testing is frequently used in emergency situations to aid clinical decision-making, often performed by nurses or clinical team members rather than physicians. These circumstances can lead to incorrect order and result documentation, potentially resulting in misdiagnoses and affecting the quality of patient care. Due to these concerns, patients and doctors may opt against point-of-care testing. This represents one of the most significant barriers to the increased adoption of point-of-care testing.

Market Trends of the Global Point of Care Diagnostics (POCD) Market

Major market participants are increasingly focusing on integrating new technologies, such as artificial intelligence, into the production of efficient point-of-care diagnostics. Innovations like lab-on-a-chip platforms, wearable technologies, and smartphone integration have led to significant advancements in point-of-care testing devices. This trend is paving the way for future transformations, with cloud-based intelligent systems offering numerous possibilities for further revolutions. The development of new diagnostic systems has been influenced by the miniaturization of chip technology, advancements in microfluidics, and innovative biosensors. Lab-on-a-chip technology, particularly in infectious disease detection, is a key driver of POCT. This technology enables the use of microbiological culture, enzyme-linked immunosorbent assays (ELISA), and polymerase chain reaction (PCR) directly at the point of care.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• Patent Analysis
• Case Study Analysis
• Customer & Buying Criteria Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Point of Care Diagnostic Market by Sample

• Market Overview
• Blood Samples
• Urine Samples
• Nasal & Oropharyngeal Swabs
• Other Samples

Point of Care Diagnostic Market by Product

• Market Overview
• Glucose Monitoring Products
  • Strips
  • Meters
  • lancets & lancing devices
• Covid-19 Testing Products
• Cardiometabolic Monitoring Products
  • Cardiac Marker Testing Products
  • Blood Gas/Electrolyte Testing Products
  • HBA1C Testing Products
• Infectious Disease Testing Products
  • HIV Testing Products
  • Respiratory Infection Testing Products
  • Hepatitis C Testing Products
  • Healthcare-Associated Infection Testing Products
  • Influenza Testing Products
  • Tropical Disease Testing Products
  • Sexually Transmitted Disease Testing Products
  • Syphilis testing products
  • Syphilis testing products
  • Chlamydia trachomatis testing products
  • Herpes simplex virus (HSV) testing products
  • Tuberculosis
  • Clostridium Difficile Infection Testing Products
  • Other Infectious Disease Testing Products
• Coagulation Monitoring Products
  • PT/INR Testing Products
  • ACT/APTT Testing Products
• Pregnancy & Fertility Testing Products
  • Pregnancy Testing Products
  • Fertility Testing Products
  • Tumor/Cancer Marker Testing Products
  • Urinalysis Testing Products
  • Cholesterol Testing Products
  • Hematology Testing Products
  • Drugs-Of-Abuse Testing Products
  • Thyroid-Stimulating Hormone Testing Products
  • Fecal Occult Testing Products
  • Other Products

Point of Care Diagnostic Market by End User

• Market Overview
• Clinical Laboratories
• Ambulatory Care Facilities and Physicians Offices
• Pharmacies, Retail Clinics, And E-Commerce Platforms
• Hospitals, Critical Care Centers, And Urgent Care Centers
• Home Care Settings and Self-Testing
• Other End Users

Point of Care Diagnostic Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quidel Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffman-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chembio Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EKF Diagnostics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trinity Biotech plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instrumentation Laboratory (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nova Biomedical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTS Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sekisui Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ortho Clinical Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trividia Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chembio Diagnostic Systems, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments